arrow
K

Kazutoyo Miura

national institutes of health
H指数:60
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anti-malaria antibody engineering broadens recognition motifs and reveals new homotypic interactions that enhance protective breadth

抗疟疾抗体工程拓宽了识别基序并揭示了增强保护广度的新型同型相互作用

2026-07-280
OA
Epitope-selective vaccine designs to elicit protective antibodies against the Plasmodium falciparum circumsporozoite protein

针对恶性疟原虫环子孢子蛋白的表位选择性疫苗设计以诱导保护性抗体

2026-07-030
OA
IgG and IgM responses to PfEMP1 domains associated with semi-immunity to clinical malaria in Burkinabe children under five

IgG和IgM对与布基纳法索五岁以下儿童临床疟疾半免疫相关的PfEMP1结构域的反应

2026-04-030
OAAI
A stabilized tandem antigen chimera that elicits potent malaria transmission-reducing activity

一种稳定的串联抗原嵌合体,可引发有效的疟疾传播减少活性

2026-01-240
OAAI
Seroprevalence of antibodies to Plasmodium falciparum transmission-blocking target proteins Pfs230D1M and Pfs48/45 in Tanzanian populations of diverse malaria transmission intensity

恶性疟原虫Pfs230D1M和Pfs48/45传播阻断靶蛋白抗体的血清流行率:坦桑尼亚不同疟疾传播强度人群的研究

2025-09-190
OAAI
Priming or Boosting Plasmodium falciparum Transmission-Blocking Responses With Recombinant Vaccines or Gametocyte Extract

利用重组疫苗或配子体提取物对恶性疟原虫传播阻断反应进行预激活或增强

2025-07-010
PRE
Magnitude and durability of ProC6C-AlOH/Matrix-M™ vaccine-induced malaria transmission-blocking antibodies in Burkinabe adults from a Phase 1 randomized trial

ProC6C-AlOH/Matrix-M™疫苗诱导的疟疾传播阻断抗体的滴度与持久性:来自一项1期随机试验的布基纳法索成人数据

2025-04-100
OA
Cross-reactivity of rPvs48/45, a recombinant Plasmodium vivax protein, with plasma from Plasmodium falciparum endemic areas of Africa

重组Plasmodium vivax蛋白rPvs48/45与来自非洲Plasmodium falciparum流行区血浆的交叉反应性

2025-03-180
OA
Pyrimidine Azepine Targets the Plasmodium bc 1 Complex and Displays Multistage Antimalarial Activity
JACS AU
IF8.7
2024-10-070
OAAI
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, 1b trial
2024-10-017
OAAI
Autoantibodies inhibit Plasmodium falciparum growth and are associated with protection from clinical malaria
IMMUNITY
IF26.3
2024-08-012
PRE